Pharmaceuticals

Sanofi is considering the acquisition of Insmed for over 30 billion dollars

Shares in the US biotech company surged on the stock market, rising by over 24 per cent following the rumours, whilst Sanofi fell by 2.85 per cent in Paris.

Sanofi ricercatori in laboratorio, ricerca produzione farmaci. (Imagoeconomica)

3' min read

Translated by AI
Versione italiana

3' min read

Translated by AI
Versione italiana

Sanofi is considering the largest acquisition in the biopharmaceutical sector. The target is Insmed, a global biopharmaceutical company based in New Jersey (United States), specialising in the research, development and commercialisation of therapies for lung, respiratory, inflammatory and immunological conditions. The Paris-based group is evaluating the deal, which could take weeks to finalise and could be worth over 30 billion. On Wall Street, Insmed’s share price reacted to the rumours with a 24 per cent surge, pushing its market capitalisation above 31 billion, whilst Sanofi in Paris closed the trading session down 2.85 per cent, with a market capitalisation of 101 billion.

The hunt for the next blockbuster

The proposed deal forms part of Sanofi’s strategy to strengthen its portfolio through acquisitions, at a time when major pharmaceutical companies are striving to identify new blockbuster drugs to offset the future erosion of revenues linked to the expiry of patents. For the French group, the key issue is Dupixent, its flagship drug for asthma and skin conditions, which is set to lose its exclusivity in the early years of the next decade. Investors have long been anticipating a significant acquisition, involving assets at an advanced stage of development and with commercial prospects capable of sustaining growth in the medium to long term.

Loading...

The strategy was also reiterated by CEO Belén Garijo, who, during the conference call on the third-quarter results, highlighted M&A as a driver of growth. Having taken the helm at the start of the year following Paul Hudson’s departure, Garijo is tasked with revitalising research and development productivity, following a period of costly investment that failed to deliver the expected results. The executive, who previously led Merck, has initiated a review of the pipeline, discontinuing certain programmes deemed unpromising and appointing Paulo Fontoura, formerly of Roche, to head up research and development in place of Houman Ashrafian.

Sanofi has significant financial capacity to support an acquisition of this scale. The sale of a controlling stake in Opella, its consumer healthcare division, to the private equity firm Clayton Dubilier & Rice generated approximately €10 billion in net proceeds. Chief Financial Officer François-Xavier Roger recently hinted that the group is prepared to consider larger transactions than in the past: ‘The stakes are higher than those we have pursued previously.’

The reorganisation also affects the internal structure and the pace of new drug development. Sanofi aims to launch up to 15 early-stage clinical trials in humans each year, in order to shorten development times and bolster the pipeline. The path remains bumpy, however: some trials have fallen short of expectations, including those on amlitelimab, an experimental drug for atopic dermatitis, and on a treatment for a rare autoimmune disease. By the end of the year, the group is expected to present an update on its strategic priorities, whilst the market awaits clarification on whether the search for a new blockbuster will involve a transformative operation such as the one currently under consideration regarding Insmed. Sanofi shares are up 1.75 per cent year-to-date, but have gained 18 per cent in the last month alone.

Insmed, for its part, has seen its share price surge over the past month, posting a 50 per cent rise (including today’s jump) after revising upwards the lower limit of its revenue forecasts for 2026 for Brinsupri and Arikayce, two medicines intended for the treatment of lung conditions. The company has also recently appointed Paul Hudson, the former CEO of Sanofi, to its board as an independent director. This move adds an element of interest to the potential deal, although it does not indicate any direct involvement in the negotiations.

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti